Paul Brunetta

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

John H. Stone, Peter A. Merkel, Robert Spiera et al. · New England Journal of Medicine · 2010 · 2.7K citations · Full text

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

Brad H. Rovin, Richard Furie, Kevin Latinis et al. · Arthritis & Rheumatism · 2012 · 1.4K citations

Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

Joan T. Merrill, C. Michael Neuwelt, Daniel J. Wallace et al. · Arthritis & Rheumatism · 2009 · 1.3K citations · Full text

Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis

Ulrich Specks, Peter A. Merkel, Philip Seo et al. · New England Journal of Medicine · 2013 · 713 citations · Full text

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Richard Furie, Gustavo Aroca, Matthew D. Cascino et al. · Annals of the Rheumatic Diseases · 2022 · 392 citations · Full text